# Lewis y Antibody [clone LWY/1463] (V3337)

| Catalog No. | Formulation | Size |
|---|---|---|
| V3337-100UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide | 100 ug |
| V3337-20UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide | 20 ug |
| V3337SAF-100UG | 1 mg/ml in 1X PBS; BSA free, sodium azide free | 100 ug |

**Bulk quote request**

| | |
|---|---|
| **Availability** | 1-3 business days |
| **Species Reactivity** | Human |
| **Format** | Purified |
| **Clonality** | Monoclonal (mouse origin) |
| **Isotype** | Mouse IgG1, kappa |
| **Clone Name** | LWY/1463 |
| **Purity** | Protein G affinity chromatography |
| **UniProt** | Not Applicable |
| **Localization** | Cell membrane, cytoplasmic and extracellular |
| **Applications** | Immunohistochemistry (FFPE) : 0.5-1ug/ml for 30 min at RT |
| **Limitations** | This Lewis y antibody is available for research use only. |



IHC testing of FFPE human lung carcinoma with Lewis y antibody (clone LWY/1463). Required HIER: boil tissue sections in 10mM citrate buffer, pH 6, for 10-20 min.

## Description

This antibody recognizes a carbohydrate epitope present on tumor-associated Lewis Y antigen (Fucalpha1-2Galbeta1-4/3[Fucalpha1-3/4]GlcNAcbeta-). Lewis Y is expressed in large bowel tumors and colorectal

carcinomas. It may be useful in the classification of human renal and bladder tumors. The Lewis Y antigen has been evaluated as a clinical marker for the diagnosis and prognosis of cholangiocarcinoma, hepatocellular carcinoma and breast cancer.

## Application Notes

Optimal dilution of the Lewis y antibody should be determined by the researcher.

## Immunogen

Human colon carcinoma cells were used as the immunogen for the Lewis y antibody.

## Storage

Store the Lewis y antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).